Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 25 01:37PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-5.37 Insider Own1.98% Shs Outstand96.48M Perf Week-2.66%
Market Cap2.36B Forward P/E- EPS next Y-5.45 Insider Trans-2.80% Shs Float94.57M Perf Month-1.53%
Income-485.50M PEG- EPS next Q-1.21 Inst Own91.38% Short Float15.54% Perf Quarter-8.68%
Sales52.60M P/S44.94 EPS this Y5.32% Inst Trans-0.30% Short Ratio10.05 Perf Half Y-18.87%
Book/sh10.76 P/B2.28 EPS next Y-6.27% ROA-36.27% Short Interest14.70M Perf Year-40.21%
Cash/sh8.20 P/C2.99 EPS next 5Y30.00% ROE-43.60% 52W Range19.37 - 46.50 Perf YTD-19.65%
Dividend Est.- P/FCF- EPS past 5Y-22.30% ROI-43.03% 52W High-47.31% Beta1.83
Dividend TTM- Quick Ratio9.03 Sales past 5Y12.09% Gross Margin82.06% 52W Low26.48% ATR (14)1.29
Dividend Ex-Date- Current Ratio9.03 EPS Y/Y TTM0.38% Oper. Margin-983.45% RSI (14)51.54 Volatility4.31% 5.19%
Employees526 Debt/Eq0.11 Sales Y/Y TTM-1.63% Profit Margin-922.94% Recom1.52 Target Price69.25
Option/ShortYes / Yes LT Debt/Eq0.09 EPS Q/Q4.25% Payout- Rel Volume0.67 Prev Close25.00
Sales Surprise157.37% EPS Surprise18.02% Sales Q/Q129.53% EarningsMay 09 BMO Avg Volume1.46M Price24.50
SMA203.03% SMA503.89% SMA200-10.91% Trades Volume636,427 Change-2.00%
Date Action Analyst Rating Change Price Target Change
Feb-23-24Downgrade Goldman Buy → Neutral $136 → $32
Feb-15-24Initiated Wolfe Research Peer Perform
Apr-13-23Initiated Canaccord Genuity Buy $66
Mar-21-23Initiated Bernstein Outperform $54
Mar-14-23Upgrade BMO Capital Markets Market Perform → Outperform $54 → $57
Feb-01-23Initiated Cantor Fitzgerald Overweight $67
Jan-24-23Upgrade Citigroup Sell → Neutral $48 → $39
Jan-19-23Downgrade JMP Securities Mkt Outperform → Mkt Perform
Oct-11-22Initiated Morgan Stanley Overweight $84
Sep-21-22Initiated JP Morgan Overweight $85
Today 08:00AM
Jun-21-24 06:30AM
Jun-17-24 07:30AM
Jun-14-24 11:49AM
06:20AM Loading…
Jun-09-24 06:20AM
Jun-08-24 07:25AM
Jun-07-24 11:25AM
Jun-06-24 11:05AM
Jun-05-24 01:35PM
Jun-04-24 11:21AM
Jun-03-24 04:31PM
Jun-02-24 08:00AM
08:30AM Loading…
May-25-24 08:30AM
May-22-24 11:15AM
May-14-24 12:46PM
May-13-24 02:18PM
May-10-24 03:35PM
May-09-24 11:53PM
May-03-24 06:15PM
02:18PM Loading…
May-02-24 07:30AM
Apr-29-24 07:30AM
Apr-25-24 11:21AM
Apr-14-24 05:55AM
Apr-12-24 04:50AM
Apr-09-24 04:50AM
Mar-28-24 05:55AM
Mar-21-24 05:29PM
Mar-19-24 01:06PM
Mar-18-24 07:30AM
Mar-09-24 09:45AM
Mar-06-24 10:35AM
Mar-01-24 01:43PM
Feb-29-24 05:50AM
Feb-28-24 09:30AM
Feb-27-24 11:55AM
Feb-23-24 12:22PM
Feb-22-24 10:53PM
Feb-20-24 05:02AM
Feb-17-24 01:59AM
Feb-15-24 10:00AM
Feb-14-24 07:30AM
Feb-13-24 06:05AM
Feb-10-24 05:09PM
Feb-08-24 01:15PM
Feb-07-24 11:50AM
Feb-05-24 05:25AM
Jan-31-24 05:00PM
Jan-30-24 05:10AM
Jan-29-24 09:35AM
Jan-27-24 01:25PM
Jan-24-24 07:00AM
Jan-22-24 05:41PM
Jan-21-24 08:00AM
Jan-18-24 11:50AM
Jan-13-24 06:05AM
Jan-12-24 08:44AM
Jan-08-24 07:45AM
Jan-05-24 10:04AM
Jan-04-24 04:01PM
Dec-31-23 08:45AM
Dec-27-23 06:41PM
Dec-16-23 05:00AM
Dec-13-23 05:20AM
Dec-12-23 06:00AM
Dec-10-23 11:57AM
Nov-28-23 05:30AM
Nov-24-23 07:00AM
Nov-15-23 11:07AM
Nov-14-23 07:30AM
Nov-10-23 05:38PM
Nov-09-23 04:06PM
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Verwiel FrankDirectorJun 17 '24Sale25.001,50537,62517,948Jun 20 05:00 PM
BASTA JAMESEVP, General CounselMar 04 '24Sale32.992,29775,77881,571Mar 05 04:10 PM
Clark ElianaEVP, Chief Technical OfficerMar 04 '24Sale32.9960519,95971,470Mar 05 04:10 PM
Sepp-Lorenzino LauraEVP, Chief Scientific OfficerJan 08 '24Sale28.872,27565,68243,927Jan 10 04:15 PM
LEONARD JOHN MPresident and CEOJan 03 '24Sale29.4619,223566,310846,486Jan 05 04:51 PM
Lebwohl DavidEVP, Chief Medical OfficerJan 03 '24Sale29.465,843172,13554,372Jan 05 04:50 PM
Sepp-Lorenzino LauraEVP, Chief Scientific OfficerJan 03 '24Sale29.465,532162,97346,202Jan 05 04:50 PM
Goddard GlennEVP, Chief Financial OfficerJan 03 '24Sale29.465,365158,05340,585Jan 05 04:49 PM
Clark ElianaEVP, Chief Technical OfficerJan 03 '24Sale29.504,608135,95440,845Jan 05 04:44 PM
Hicks DerekEVP, Chief Business OfficerJan 03 '24Sale29.463,877114,21636,987Jan 05 04:46 PM
BASTA JAMESEVP, General CounselJan 03 '24Sale29.463,805112,09551,474Jan 05 04:45 PM
Bhanji MunaDirectorOct 31 '23Sale23.902656,33411,996Nov 02 04:42 PM
Bhanji MunaDirectorJul 31 '23Sale42.3326511,21712,261Aug 02 05:19 PM
Bhanji MunaDirectorJul 06 '23Sale39.301,86773,37312,526Jul 10 05:21 PM
Clark ElianaEVP, Chief Technical OfficerJul 03 '23Sale40.5136014,58445,146Jul 06 03:34 PM